Kanabo Grp Plc Regulatory News (KNB)

8 April 2021

Kanabo Group PLC

("Kanabo" or the "Company")

Q1 Summary

Kanabo Group Plc, a medical cannabis R&D Company that focuses on the distribution of cannabis-derived products for medical patients, and non-THC products for CBD consumers, has today published a Q1 summary newsletter, detailing its recently announced agreements and further news on the Company. The Company believes that the past month since listing has been an exciting one, having announced several key steps forward that the Company is taking in order to enable it to deliver value to shareholders. Kanabo expects to continue actively working on partnerships and on strengthening its team, as well as other goals outlined in their newsletter. Details can also be found on news features and upcoming events featuring Kanabo, as well as a discussion of relevant industry news.

Copies of the full newsletter will be available to download from the Company's website at www.kanabogroup.com. An email registration facility is also available on the Company's website to directly receive updates.

For further information, please visit http://www.kanabogroup.com/ or contact the following:

Kanabo Group Plc

+(972)52-3173-633

press@kanabogroup.com

Meirav Horn

Peterhouse Capital Limited (Financial Adviser)

Tel: +44 (0)20 7469 0930

Eran Zucker / Guy Miller / Allie Feuerlein

Peterhouse Capital Limited (Corporate Broker)

Lucy Williams / Charles Goodfellow

About Reach announcements

This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the Listing Rules, Disclosure and Transparency Rules, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.